Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $9.27B
• Dividend Yield: N/A
• Average Volume (3M): 45.45M
• Price to Earnings (P/E): 60.3
• Beta (1Y): 3.06
• Revenue Growth: 85.99%
• EPS Growth: N/A
• Country: US
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 46
• Industry: Household & Personal Products
• EPS (TTM): 0.20
• Shares Outstanding: 215,453,900
• 10 Day Avg. Volume: 52,676,471
• 30 Day Avg. Volume: 45,452,819
• PEG Ratio: 0.45
• Price to Book (P/B): 4.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -38.81
• Enterprise Value/Market Cap: 0.02
• Enterprise Value/Revenue: 0.04
• Enterprise Value/Gross Profit: 0.17
• Enterprise Value/Ebitda: 0.78
• 1Y Price Target: $39.80
• Price Target Upside: -3.89% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 11

• Rating: 72 Outperform
• Price Target: $47.00 ▲(13.50%Upside)

Hims & Hers Health's overall stock score is driven by strong financial performance and strategic growth initiatives. The company's robust revenue growth, improved profitability, and strategic partnerships in expanding markets are key strengths. Nevertheless, high valuation multiples and potential margin pressures present risks. Positive corporate events and a bullish technical setup further support the stock's outlook, while cautious valuation assessments and upcoming challenges should be monitored.

Positive Factors

Growth Opportunities

The risk-reward at the current levels looks compelling with the forward EV/revenue multiple compressing by two turns in a single trading session.

Guidance

Analysts believe FY25 guidance is achievable even without the Novo partnership, and the company has multiple levers to accelerate core growth.

Negative Factors

Legal Risks

Novo cited that HIMS engaged in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.'

Partnership Termination

Novo Nordisk announced that it has terminated its partnership with Hims & Hers due to concerns over the company's compounding and marketing practices.

Revenue Impact

HIMS shares sold off nearly 35% on the news of the terminated partnership, driven by concerns around the near-term revenue impact and a revitalized litigation risk.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health (HIMS) is a telehealth company that operates in the healthcare and wellness sectors. The company provides a digital platform offering a range of health and wellness services, including prescription and over-the-counter medication, personal care products, and access to licensed healthcare professionals. Their services target common conditions such as hair loss, sexual health, skin care, and mental health, providing consumers with convenient and affordable healthcare solutions.

How the Company Makes Money

Hims & Hers Health generates revenue primarily through the sale of its products and services via its online platform. The company's business model includes a direct-to-consumer approach, where customers can subscribe to monthly plans for recurring shipments of prescription medications and personal care products. Revenue streams are diversified across various health categories, including sexual health, dermatology, mental health, and primary care. Key factors contributing to its earnings include its ability to leverage telemedicine to reduce costs and improve accessibility, its subscription-based model that ensures recurring revenue, and strategic partnerships with healthcare professionals and pharmaceutical companies to broaden its service offerings.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health shows strong revenue growth of 20.86% with improving profitability metrics, backed by a solid balance sheet with low leverage and increasing equity. However, past negative earnings and equity pose potential risks.

Income Statement

Hims & Hers Health has demonstrated robust revenue growth and improving profitability. Over the TTM, total revenue increased significantly by 20.86% from the previous annual period. The company's gross profit margin stood at 74.73%, and the net profit margin improved to 9.21%. Additionally, the EBIT margin increased to 6.19%, indicating better operational efficiency. However, historical losses and fluctuating margins in previous years pose a potential risk.

Balance Sheet

The balance sheet shows a healthy equity position with an equity ratio of 61.58%, indicating strong financial stability. The debt-to-equity ratio is low at 0.12, reflecting conservative leverage. Return on equity improved to 29.92%, suggesting effective use of equity to generate profits. The increase in stockholders' equity over time highlights the company's capital strength. However, past negative equity and liabilities exceeding assets in earlier years should be noted.

Cash Flow

Hims & Hers Health's cash flow from operations has consistently improved, with a significant increase in free cash flow by 14.68% over the latest period. The operating cash flow to net income ratio is robust at 2.03, demonstrating strong cash generation relative to earnings. The company has maintained positive free cash flow, indicative of good cash management practices. Past periods of negative free cash flow and operational cash flow constraints may pose risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.78B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.37B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	132.26M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	164.40M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	891.71M	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	322.67M	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	63.38M	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	342.45M	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	549.26M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	240.22M	209.43M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	334.34M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-64.89M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	-100.56M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 41.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 41.41 is below the 20-day moving average (MA) of 54.47, below the 50-day MA of 48.06, and above the 200-day MA of 33.74, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 36.76 is Neutral, neither overbought nor oversold. The STOCH value of 1.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPAR	82 Outperform	$4.28B	25.87	22.16%	2.40%	10.32%	18.55%
ELF	75 Outperform	$7.03B	65.03	15.97%	―	28.28%	-14.79%
HIMS	72 Outperform	$9.27B	60.28	36.79%	―	85.99%	―
EPC	65 Neutral	$1.11B	13.88	5.53%	2.52%	-2.11%	-28.79%
NUS	62 Neutral	$381.96M	―	-4.93%	3.10%	-11.85%	-1080.00%
COTY	56 Neutral	$4.05B	40.12	-10.58%	―	-1.68%	-302.11%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%

Hims & Hers Health Corporate Events

Hims & Hers Health Annual Stockholders Meeting Results

On June 12, 2025, Hims & Hers Health, Inc. conducted its Annual Meeting of Stockholders where three proposals were voted on. The election of eight directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the advisory approval of executive compensation were all passed, reflecting shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Health Issues $1 Billion in Notes

On May 13, 2025, Hims & Hers Health issued $1 billion in senior unsecured notes, which are equal in payment rights to the company’s existing and future senior unsecured debts but are subordinate to secured debts. These notes, maturing on May 15, 2030, offer conversion options into Class A common stock under specific conditions and include provisions for redemption and repurchase under certain corporate events. Additionally, the company engaged in capped call transactions to mitigate potential stock dilution from note conversions, with a cap price set at $89.95 per share, representing a 75% premium over the stock’s last reported sale price on May 8, 2025.

The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.

Hims & Hers Announces $450M Convertible Notes Offering

On May 8, 2025, Hims & Hers Health, Inc. announced a proposed private offering of $450 million in Convertible Senior Notes due 2030, aimed at qualified institutional buyers. The proceeds from this offering are intended to support the company’s global expansion and investment in AI and personalized healthcare solutions, reflecting Hims & Hers’ strategic focus on scaling access to high-quality, personalized care. The offering is expected to enhance the company’s market positioning by funding organic growth and potential acquisitions, although no definitive acquisition agreements are in place at this time.

Hims & Hers Health COO Transition to Advisory Role

On April 21, 2025, Melissa Baird, the Chief Operating Officer of Hims & Hers Health, announced her plan to transition into an advisory role with the company. Her departure date is yet to be determined, but she will remain until a successor is found to ensure a smooth transition, and a long-term agreement will be established to retain her expertise.